Bonyf NV (MLBON) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Bonyf NV stock €1.84, price €1.90, that is 3.2% below the price, quality 42 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Bonyf NV
MLBON · PAThe stock is already about fairly priced, weak company and price moving sideways: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
56‑month range €1.80 – €19.50 · fair‑value band €1.38 – €2.30 · the €1.90 price screens above the €1.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Bonyf is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
bonyf N.V. engages in the research, development, production, and distribution of oral and dental products in Belgium and internationally.
Show moreShow less
The company offers PerioTabs, a brushing solution for gums, teeth, and dental implants to help reduce gingivitis, periodontitis, peri-mucositis, and peri-implantitis; and AphtoFix, a film-forming cream for the local treatment of mouth ulcers.
It also provides denture care products, such as OlivaFix denture adhesive creams and NitrAdine disinfecting denture tabs; Denture Repair-fix, an instant repair system for broken or cracked dentures and teeth detached from dentures; Fixobridge, a ready to use cement that fixes dislodged crowns, inlays, and bridges; denture relining cushion for ill-fitting dentures; Effervescent denture cleanser tablets; Superior denture adhesive creams; and Cavifix, a synthetic resin-based filling material to temporarily seal newly formed cavities and repair lost fillings or inlays.
In addition, the company offers orthodontic care products, including NitrAdine Ortho & Junior disinfecting tabs to clean and disinfect removable orthodontic appliances; and wound care products comprising HeelFix and FingerFix paste dressing products for cracks and chapped skin on feet and hands. bonyf N.V. was incorporated in 1979 and is headquartered in Knokke-Heist, Belgium.
Stock analysis
Bonyf NV (MLBON) currently trades at €1.90, while our estimate is €1.84, so the stock looks roughly fairly valued today (gap 3.3%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: €1.38 (bear) to €2.30 (bull), the price of €1.90 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Bonyf NV reported revenue of €281K in FY2024 versus €3.2M in FY2019, a compound −38.5%/yr. Reported net income was −€36.5K in FY2024.
Key figures
Market cap €1.1M Micro · P/S ratio 3.61 · EPS (TTM) €−0.0200 · Net margin −13.0% · Return on equity −32.6% · Return on assets (EBIT) 0.6% (5-year average) · Operating margin −12.9% · Revenue (TTM) €309K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 85% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −3%, MLBON screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch MLBON, get fair value alerts →
Compare Bonyf NV with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 199 stocks
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- PEG screener for stocks with fair value
- Undervalued stocks: French Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Solventum Corporation SOLV | $88.65 | $131.27 | +48% | vs MLBON |
| EssilorLuxottica Société anonyme EL | €184.50 | €196.22 | +6% | vs MLBON |
| Intuitive Surgical, Inc ISRG | $437.75 | $353.90 | −19% | vs MLBON |
| Medline Inc MDLN | $39.17 | $28.59 | −27% | vs MLBON |
| Alcon Inc ALC | CHF 62.14 | CHF 35.08 | −44% | vs MLBON |
| Becton, Dickinson and Company BDX | $216.47 | $97.80 | −55% | vs MLBON |
| Straumann Holding STMN | CHF 108.75 | CHF 45.50 | −58% | vs MLBON |
| West Pharmaceutical Services, Inc WST | $417.80 | $139.22 | −67% | vs MLBON |
| Sartorius Stedim Biotech S.A DIM | €225.20 | €54.82 | −76% | vs MLBON |
| Sartorius Aktiengesellschaft SRT | €226.50 | €46.44 | −80% | vs MLBON |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Bonyf NV (MLBON) overvalued or undervalued?
What is the fair value of MLBON?
What is the quality score of MLBON?
What is the price target for Bonyf NV (MLBON)?
What is the Bonyf NV stock forecast for 2026?
What is the revenue of Bonyf NV (MLBON)?
What is the intrinsic value of Bonyf NV (MLBON)?
Is Bonyf NV stock overvalued or undervalued in 2026?
Is fair value the same as the market price of MLBON?
How much is Bonyf NV worth?
What do the bullish and bearish scenarios say about MLBON?
How solid is the balance sheet of Bonyf NV (MLBON)?
How far is MLBON from its 52-week high?
Which stocks are comparable to Bonyf NV?
Is Bonyf NV stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Bonyf NV (MLBON)?
What should I pay attention to with Bonyf NV right now?
Key figures of Bonyf NV
How large is the market capitalisation of Bonyf NV (MLBON)?
What is the P/S ratio of Bonyf NV (MLBON)?
What are the earnings per share of Bonyf NV (MLBON)?
What is the net margin of Bonyf NV (MLBON)?
What is the return on equity of Bonyf NV (MLBON)?
What is the EBIT return on assets of Bonyf NV (MLBON)?
What is the operating margin of Bonyf NV (MLBON)?
How much net debt does Bonyf NV (MLBON) carry?
Watch Bonyf NV in the live analysis
One click puts Bonyf NV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.